Skip to main content
VCOM Campus

Vikas Sehdev, PhD

Portrait of Vikas Sehdev
Vikas Sehdev, PhD
Associate Professor for Pharmacology
Department/Discipline: Pharmacology
Campus: Carolinas
Office: 149
Fax: 864-804-6986
Email: Contact

Research Interests

I am an Associate Professor of Pharmacology at Edward Via College of Osteopathic Medicine, Spartanburg, SC with dedicated research space at Gibbs Cancer Center and Research Institute located within the Spartanburg Regional Healthcare System. I have extensive experience in the disciplines of pharmacy, pharmaceutical sciences, cancer biology and therapeutics, with specific training and expertise in characterizing the anticancer effect of novel investigational anticancer agents alone or in combination with established chemotherapeutic agents. My research includes usage of big-data analysis to identify novel therapeutic targets for development of new anticancer agents and therapies. As a PI or co-Investigator on several projects that were conducted in collaboration with pharmaceutical industry partners, I laid the groundwork for clinical development of Alisertib, a novel Aurora kinase A (AURKA) inhibitor as a single agent and in combination with Cisplatin or Docetaxel for treatment of gastric and esophageal adenocarcinoma. In addition, I also characterized the oncogenic potential of AURKA by investigating its role in mediating cell death, resistance, invasion, and inflammation in various models of Upper Gastrointestinal Adenocarcinoma (UGC). This work lead to several podium presentations and multiple high impact publications. My expertise in developing and characterizing drug combinations has led to collaborative work with pharmaceutical industry partners. This body of work was presented multiple times at AACR and reported in various investor documents. The current focus of my work is aimed at improving treatment options for UGC patients by developing novel synergistic during combinations with traditional chemotherapeutic agents and repurposed pharmaceutical entities by using 2D and 3D cancer models. My training and research expertise in the disciplines of pharmacology and cancer therapeutics is an important asset in characterizing and identifying the proper dosing regimen to achieve synergistic anticancer activity in vitro and in vivo. This work will lay the groundwork for further clinical development of such drug combinations.